-
EP3749301
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3749301
| EP3749301 - PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 23.02.2024 Database last updated on 14.06.2024 | |
| Former | Request for examination was made Status updated on 13.11.2020 | ||
| Former | The international publication has been made Status updated on 10.08.2019 | ||
| Former | unknown Status updated on 05.03.2019 | Most recent event Tooltip | 27.02.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, MA 02210 / US | [2020/51] | Inventor(s) | 01 /
CHU, Cathy 50 Northern Avenue Boston, Massachusetts 02210 / US | 02 /
DHAMANKAR, Varsha 50 Northern Avenue Boston, Massachusetts 02210 / US | 03 /
DOKOU, Eleni 50 Northern Avenue Boston, Massachusetts 02210 / US | 04 /
HASELTINE, Eric L. 50 Northern Avenue Boston, Massachusetts 02210 / US | 05 /
MOSKOWITZ, Samuel 50 Northern Avenue Boston, Massachusetts 02210 / US | 06 /
ROBERTSON, Sarah 50 Northern Avenue Boston, Massachusetts 02210 / US | 07 /
WALTZ, David 50 Northern Avenue Boston, Massachusetts 02210 / US | 08 /
CHEN, Weichao George 50 Northern Avenue Boston, Massachusetts 02210 / US | [2020/51] | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [N/P] |
| Former [2020/51] | Oates, Edward Christopher Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | Application number, filing date | 19706111.2 | 04.02.2019 | [2020/51] | WO2019US16537 | Priority number, date | US201862626567P | 05.02.2018 Original published format: US 201862626567 P | US201862657522P | 13.04.2018 Original published format: US 201862657522 P | [2020/51] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019152940 | Date: | 08.08.2019 | Language: | EN | [2019/32] | Type: | A1 Application with search report | No.: | EP3749301 | Date: | 16.12.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 08.08.2019 takes the place of the publication of the European patent application. | [2020/51] | Search report(s) | International search report - published on: | EP | 08.08.2019 | Classification | IPC: | A61K31/404, A61K31/443, A61K31/4439, A61K31/47, A61P11/00 | [2020/51] | CPC: |
A61K31/4045 (EP,IL,US);
A61K31/404 (EP,IL,US);
A61K31/443 (EP,IL,US);
A61K31/4439 (EP,IL,US);
A61K31/47 (EP,IL,US);
A61P11/00 (EP,IL,US);
| C-Set: |
A61K31/404, A61K2300/00 (US,EP);
A61K31/4439, A61K2300/00 (EP,US);
A61K31/443, A61K2300/00 (US,EP);
A61K31/47, A61K2300/00 (US,EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/51] | Extension states | BA | 01.09.2020 | ME | 01.09.2020 | Validation states | KH | 01.09.2020 | MA | 01.09.2020 | MD | 01.09.2020 | TN | 01.09.2020 | Title | German: | PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON ZYSTISCHER FIBROSE | [2020/51] | English: | PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | [2020/51] | French: | COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT DE LA FIBROSE KYSTIQUE | [2020/51] | Entry into regional phase | 01.09.2020 | National basic fee paid | 01.09.2020 | Designation fee(s) paid | 01.09.2020 | Examination fee paid | Examination procedure | 01.09.2020 | Examination requested [2020/51] | 01.09.2020 | Date on which the examining division has become responsible | 31.03.2021 | Amendment by applicant (claims and/or description) | 22.02.2024 | Despatch of a communication from the examining division (Time limit: M04) | Fees paid | Renewal fee | 01.09.2020 | Renewal fee patent year 03 | 25.02.2022 | Renewal fee patent year 04 | 27.02.2023 | Renewal fee patent year 05 | 27.02.2024 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [IY]US2016095858 (MILLER MARK THOMAS [US], et al) [I] 1-61 * abstract * * paragraphs [0002] , [0008] - [0027] - [0046] * * embodiment 155; page 236 * * paragraph [1802] * * claim - * [Y] 1-61; | [IP]WO2018107100 (VERTEX PHARMA [US]) [IP] 1-61 * abstract * * paragraphs [0012] , [0076] * * page 328; compound 29 * * page 28, paragraph 90 * * page 100, line 6 - page 106, line 8 * * claim 71 *; | [IP]WO2019018395 (VERTEX PHARMA [US]) [IP] 1-61 * the whole document * * page 119; example 8 * * page 124; example 9 * * page 130; example 10 ** claim - *; | [Y] - NOVEMBER, "Vertex Announces Presentations of Data at North American Cystic Fibrosis Conference that Demonstrate Important Progress Toward Goal of Helping All People with CF", HEALTH AND MEDICINE WEEK, US, (20171124), vol. 3, ISSN 1531-6459, page 196, XP055575225 [Y] 1-61 * page 3, lines 9-23 * | [Y] - Anonymous, "Vertex Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F508del/Min) | Vertex Pharmaceuticals", (20170718), URL: https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-positive-phase-1-phase-2-data-three-different, (20190327), XP055574958 [Y] 1-61 * the whole document * | by applicant | US2003144257 | US2004006237 | US2004105820 | WO2007134279 | WO2010019239 | WO2011019413 | WO2011119984 | WO2012027731 | WO2013130669 | WO2014015841 | US8865902 | WO2015160787 | - CUTTING, G. R. et al., Nature, (19900000), vol. 346, pages 366 - 369 | - DEAN, M. et al., Cell, (19900000), vol. 61, pages 863 - 870 | - KEREM, B-S. et al., Science, (19890000), vol. 245, pages 1073 - 1080 | - KEREM, B-S et al., Proc. Natl. Acad. Sci. USA, (19900000), vol. 87, pages 8447 - 8451 | - QUINTON, P. M., FASEB J., (19900000), vol. 4, pages 2709 - 2727 | - DALEMANS et al., Nature Lond., (19910000), vol. 354, pages 526 - 528 | - PASYK; FOSKETT, J. Cell. Biochem., (19950000), vol. 270, pages 12347 - 50 | - S. M. BERGE et al., "describe pharmaceutically acceptable salts in detail", J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19 | - S. M. BERGE et al., J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19 | - "Atomization and Spray-Drying", MARSHALL, Chem. Eng. Prog. Monogr. Series, (19540000), vol. 2, page 50 | - VAN GOAR, F. et al., PNAS, (20090000), vol. 106, no. 44, pages 18825 - 18830 | - VAN GOOR, F. et al., PNAS, (20110000), vol. 108, no. 46, pages 18843 - 18846 | - S. L. HARBESON; R. D. TUNG, "Deuterium In Drug Discovery and Development", Ann. Rep. Med. Chem., (20110000), vol. 46, doi:doi:10.1016/B978-0-12-386009-5.00003-5, pages 403 - 417, XP055422117 DOI: http://dx.doi.org/10.1016/B978-0-12-386009-5.00003-5 | - T.G. GANT, "Using deuterium in drug discovery: leaving the label in the drug", J. Med. Chem., (20140000), vol. 57, doi:doi:10.1021/jm4007998, pages 3595 - 3611, XP055139522 DOI: http://dx.doi.org/10.1021/jm4007998 | WO2017US65425 |